The table below shows CNS Pharmaceuticals, Inc.'s cash flow statement line items across its last 6 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
Line item
FY 2025
FY 2024
FY 2023
FY 2022
FY 2021
FY 2020
Operating cash flow
-$13.81M
-$17.11M
-$14.14M
-$10.56M
-$13.54M
-$7.32M
Capital expenditure
$18.18K
$4.19K
$3.90K
$4.42K
$5.75K
$17.95K
Investing cash flow
-$18.18K
-$4.19K
-$3.90K
-$4.42K
-$5.75K
-$17.95K
Dividends paid
-
-
-
-
CNSP operating cash flow (10-K history)
CNS Pharmaceuticals, Inc. reported operating cash flow of -$13.81M for fiscal year 2025. That is up 19.3% from -$17.11M in fiscal 2024. Over the 8 fiscal years shown, operating cash flow declined from -$716.38K (FY 2018) to -$13.81M. Figures come from the company's audited annual reports as filed with the SEC.